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Abstract
Background. The use of induction drugs has increased
markedly over the last 15 years in the USA, but there
are few data about their use in other countries. Moreover,
there are not enough data about when they are indicated
and their long-term effects. The aim of our study was to
know the rates of use and the drugs used as induction
therapy, in which patients they were prescribed and the
long-term graft survival effect in Spain.
Methods. We conducted a retrospective cohort study
with adult patients (4861) receiving a kidney allograft
in Spain over four different years (1990, 1994, 1998
and 2002) with a functioning graft at the end of the first
post-transplant year. Induction therapy was defined as
when the patient received polyclonal antibodies,
OKT3 monoclonal antibodies or anti-CD25 monoclonal
antibodies.
Results. From1990 to 2002, the use of induction therapyin
Spain changed, with a progressive reduction in the use of
OKT3 and an increasing use of anti-CD25 antibodies.
There were great differences in the rate of induction use
from one centre to another, although with a common trend
to greater use at each centre. Induction therapy was mainly
prescribed in patients with a higher rejection risk (higher
panel reactive antibody (PRA) titres and mismatches and
re-transplants) and in older and diabetic recipients. Lastly,
patients who were treated with induction therapy had sig-
nificant higher allograft survival than those who did not
(P value = 0.035).
Conclusions. The use of induction therapy in Spain has
changed, with an increasing use of monoclonal antibodies
in recent years. Induction therapy has a protective role in
long-term graft survival.
Keywords: basiliximab; daclizumab; induction therapy; kidney
transplantation; Thymoglobulin
Introduction
Theterm‘inductiontherapy’commonlyreferstotheadmin-
istration of antibodies against specific or multiple antigenic
targets of immune cells in the immediate peri-operative
period [1]. These antibodies have largely been used to
provide immunosuppression at the time of antigen pre-
sentation, during the initial period after solid organ trans-
plantation, with the purpose of reorienting the immune
system by depleting potentially alloreactive immune cells
[2]. Induction strategies have gained increased interest in
recent decades. Several meta-analyses have demonstrated
that induction therapy improves renal graft outcome com-
pared with conventional therapy. Antilymphocyte antibo-
dies have a beneficial effect on 2-year allograft survival,
and non-depleting antibodies, such as the anti-CD25 anti-
bodies basiliximab and daclizumab, reduce acute rejec-
tion rate [3–6]. Moreover, induction drugs play a key
role in the promising corticosteroid or calcineurin-inhib-
itor minimization strategies [7,8].
The frequency of use of the different induction drugs has
varied markedly over the last 15 years. While in the early
1990s the majority of US kidney transplant recipients did
not receive induction therapy, in 2004 nearly 72% of reci-
pients receivedsome kind of antilymphocytedrug. Current-
ly, Thymoglobulin is the most frequently used (37%)
induction agent in the USA, and anti-CD25 antibodies are
used only rarely [9]. Apart from the USA, little has been
published providing an overview of trends in induction
use. Data from the Australia and New Zealand Dialysis
and Transplant (ANZDATA) registry showed a decline in
OKT3 and polyclonal antibody use and an increase in the
prescriptionofanti-CD25 antibodiesto57.1%in2001[10].
Non-serial studies provide data about induction use in some
Asian centres (18.4%) [11], international registries (37.7%)
[12] and one South American centre (36%) [13]. One of the
aimsofourstudy wastodescribe thetrendsininduction use
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among centres.
The high rate of variation between countries and centres
in induction use revealed not only differences between
transplant populations but also differences in indication.
Some centres reserve induction therapy for patients at
high immunological risk. Other centres use lymphocyte-
depleting agents for high-risk patients and non-depleting
agentsforlow-riskpatients[1].Thelackofcommonindica-
tions for induction therapy would suggest that it is not well
known which patients should receive it and what induction
drug must be prescribed. The benefits of using induction
must be weighed against the potential risk of infection
and malignancy. Commonly, induction is used in patients
with a higher rejection risk (African-American, highly sen-
sitized patients, patients undergoing re-transplantation), a
higher delayed graft function risk (longer cold ischaemia
time, expanded criteria donors, donors after cardiac death)
or in patients under minimization immunosuppressive
strategies [1,3,14]. The second purpose of our study was
to know in which patients in Spain induction was pre-
scribed and the differences in use between polyclonal anti-
bodies and anti-CD25 antibodies.
Over the last few years, focus on kidney transplantation
has shifted towards long-term graft survival due to the im-
provements in short-term graft survival [15]. The effect of
induction antibodies over long-term graft survival is con-
troversial. By means of a meta-analysis of individual
patient-level data, Szczech etal.showedabenefitof induc-
tion at2yearsinall patients and evenat5yearsinrecipients
with panel reactive antibodies (PRA) ≥20% [3]. A single-
centre study comparing polyclonal antibody induction
against no induction demonstrated that induction improved
graft survival only during the first post-transplant year and
did not exert its effect further [16]. Antibody induction is
also associated with an elevated risk for cardiovascular
death, infection-related death and malignancy-related death
[17].Data about thelong-termeffect of inductiononpatient
and graft survival are scarce. We analysed this issue in our
Spanish kidney recipient population.
Materials and methods
We conducted a retrospective cohort study with patients receiving a kid-
ney allograft in Spain over four different years (1990, 1994, 1998 and
2002). Only adult patients (≥18 years), receiving a single kidney and
remaining alive with a functioning graft at the end of the first post-
transplant year were included in the study [18].
The following data were recorded for each patient at the time of trans-
plantation and during hospitalization until discharge by chart review: age
and gender of the donor and the recipient, source of the organ (living or
deceased donor), cause of donor death, primary kidney disease, recipient
body mass index, peak and current PRA, number of transplants, time on
renal replacement therapy, mismatches, presence of hepatitis C antibodies
in the recipient, and cold ischaemia time. Graft and patient survival, de-
layed graft function, acute rejection, first-year creatinine and first-year
hypertension were also collected from the clinical charts. Delayed graft
function was defined as the need for dialysis within the first week after
transplantation. The diagnosis of acute rejection was defined according
to the criteria of each centre based on clinical and histological data. Ar-
terial hypertension was defined as blood pressure more than 140/
90 mmHg or need for antihypertensive therapy [18].
Initial immunosuppressive therapy was recorded. Induction therapy
was defined when the patient received polyclonal antibodies (ALG,
ATG, ATGAM, Thymoglobulin), OKT3 monoclonal antibodies or anti-
CD25 monoclonal antibodies (basiliximab, daclizumab). Other induction
drugs were used under clinical trials and were excluded from the analysis.
During the study period, 4928 kidney transplant patients fulfilled the in-
clusion criteria. In 67 patients, there were inadequate data with respect to
induction therapy (data absence or duplicate), or they received different
induction drugs for clinical trials.
Medical record review was performed by a transplant physician at each
centre taking part in the study according to Spanish law with reference to
clinical data confidentiality (Spanish Official Bulletin, BOE No. 298,
1999, pp. 43088–43099). The study was conducted according to the prin-
ciples described in the Declaration of Helsinki.
StatisticalanalysiswasperformedusingSPSS8.0(SPSS,Inc.,Chicago,
IL, USA). Comparison between variables was made by using Student’s
t-test for numerical values and chi-square test for categorical data. Step-
wise multiple regression analysis was used to select independent risk
factors for receiving induction therapy among parameters selected by
univariate analysis. Graft and patient survivals were analysed using
Kaplan–Meier estimate (log rank test). Independent risk factors for graft
loss were studied by means of Cox’s regression analysis. A P value of less
than 5% was reported as statistically significant. Results were considered
statistically significant for P < 0.05.
Results
Year of transplantation
Induction therapy showed marked changes throughout the
study period (Figure 1). There were significant differences
in the percentages of transplant patients that received in-
duction therapy (25.7% in 1990, 40.7% in 1994, 27.1%
in 1998 and 37.2% in 2002, P < 0.0001) but without a
clear trend. Similarly, there were significant differences
in the percentages of transplant patients under polyclonal
antibodies (19.9% in 1990, 31.1% in 1994, 17.0% in 1998
and 9.2% in 2002, P < 0.0001). During the study period,
there was a significant reduction in the number of patients
receiving OKT3 (4.9% in 1990, 9.3% in 1994, 5.0% in
1998 and 1.0% in 2002, P < 0.0001). By contrast, a sig-
nificant increase in the percentages of patients treated with
anti-CD25 antibodies was found (1.3% in 1990, 0.9% in
1994, 5.6% in 1998 and 27.2% in 2002, P < 0.0001).
Transplant centre
Throughout the study period, there was great variability in
the use of induction therapy among the different Spanish
transplant centres. Induction use ranged from 1.6% to
98.1% (mean 36.4%) for any patient in each centre. Poly-
clonal antibody use ranged from 0% to 78% (mean 21.1%)
and anti-CD25 antibodies from 0% to 73% (mean 9.5%).
Nearly half (48.5%) of the centres used induction therapy
in less than 25% of patients, while 24.2% of the centres
used induction from 25% to 50% of patients and 27.3%
of the centres in more than half their transplant recipients.
From 1990 to 2002, the percentages of centres using in-
duction therapy in less than 25% of their patients fell from
62.9% to 39.3%, while the centres using induction therapy
with between 25% and 50% of their recipients increased
from 3.6% to 32.1%. Nearly a third of the centres treated
more than 50% of their patients with induction drugs
(33.3% in 1990 and 28.6% in 2002).
Most of the centres that treated more than 50% of their
transplant patients with induction therapy in 1990 were us-
ing polyclonal antibodies (86%). In 2002, these same cen-
ii10 E. Rodrigo et al.tres used induction treatment in 56% of patients, but only
18% of them received polyclonal antibodies, while 38%
received anti-CD25 antibodies (P < 0.01). On the other
hand, centres that used induction therapy in less than
25% of their patients (3%) in 1990 increased the use of
induction to more than a quarter of the patients (27%)
and used anti-CD25 antibodies (18%) more frequently
than polyclonal antibodies (9%).
Induction indication
The only donor characteristic related in univariate analysis
with a higher rate of induction prescription was donor age
(Table 1). We found no differences in the use of induction
according to donor sex, death cause or donor status (de-
ceased vs live-donor). No donor characteristic was related
with induction use after multivariate analysis.
Recipient characteristics related with a higher rate of in-
duction therapy were recipient age, the title of PRA, the
length of renal replacement therapy, the number of mis-
matches, the number of transplants and recipient diabetes
(Table 1). After multivariate analysis, patients whoreceived
induction more frequently were those older than 60 years
(RR 1.28, 95% CI 1.03–1.58, P = 0.0211), with more than
15% of PRA (RR 1.74, 95% CI 1.32–2.30, P = 0.0001), re-
ceivingasecondormoretransplant(RR1.47,95%CI1.11–
1.95,P=0.0061), withmoremismatches (RR1.20,95%CI
1.12–1.28, P < 0.001) and diabetic (RR 1.54, 95% CI 1.13–
2.09, P = 0.0055).
In 2002, a higher number of patients under induction
therapy received anti-CD25 antibodies (323) than poly-
clonal antibodies (104). Patients treated with polyclonal
antibodies were younger, had a higher rate of current
and peak PRA and were more frequently re-transplants
(Table 2).
Induction results
Consideringafollow-upperiodof15years(since1990)and
censoring patients with functioning graft but with a shorter
follow-up, the average time of graft survival in patients who
were treated with induction therapy has been significantly
higher than those who were not (14.092 years; IC95%=
[13.767–14.416] vs 13.595; IC95%=[13.338–13.852]; P
value = 0.035) (Figure 2). Likewise, 14% of patients
who received induction and 15.6% of patients who did
not receive induction lost their grafts. After adjusting for
delayed graft function, acute rejection, first year creatinine,
pre-transplant PRA, first year hypertension and receptor
age, the use of induction therapy remained significant as
a protective factor for graft survival (HR 0.686, 95% CI
0.587–0.801, P < 0.001). By contrast, induction therapy
was neither a risk nor a protective factor for patient survival
(log rank test P = 0.072).
Fig. 1. Trends in the percentage of patients receiving antibodies as
induction immunosuppression, 1990–2002 cohorts. Polyclonal
antibodies in white, OKT3 in black and anti-CD25 antibodies in grey.
Table 1. Donor and recipient characteristics of transplant patients
receiving induction therapy vs those not receiving
Induction
therapy
(n = 1633)
Non-induction
therapy
(n = 3228) P
Donor age (years) 43.0 ± 17.3 41.6 ± 16.7 0.010
Donor age (>60) 19.3% 16.7% 0.027
Donor sex (male) 61.7% 62.9% 0.394
Death cause (CVA) 50.6% 50.0% 0.676
Donor status (deceased) 99.0% 98.6% 0.222
Recipient age (years) 46.7 ± 14.4 45.7 ± 13.8 0.017
Recipient age (>60) 20.1% 15.7% <0.001
Current PRA 6.8 ± 18.2 3.0 ± 10.6 <0.001
Peak PRA 15.7 ± 27.5 9.1 ± 19.4 <0.001
PRA > 15% 13.5% 6.8% <0.001
RRT length 3.8 ± 4.3 3.1 ± 3.5 <0.001
Recipient diabetes 8.7% 5.8% 0.001
Transplant number (>1) 17.6% 9.7% <0.001
Recipient HCV 15.3% 11.9% 0.001
Body mass index 24.4 ± 4.0 24.6 ± 4.0 0.209
Mismatches 3.2 ± 1.2 3.0 ± 1.2 <0.001
Cold ischaemia time (hours) 19.0 ± 6.4 19.2 ± 7.2 0.393
RRT, renal replacement therapy; CVA, cerebro-vascular accident.
Table 2. Characteristics of patients receiving polyclonal antibodies or
anti-CD25 antibodies in 2002
Polyclonal
antibodies
(n = 104)
Anti-CD25
antibodies
(n = 323) P
Donor age (years) 47.3 ± 16.1 49.6 ± 16.4 0.229
Donor age (>60) 22.5% 30.7% 0.112
Donor sex (male) 55.7% 66.5% 0.046
Death cause (CVA) 55.4% 64.5% 0.139
Donor status (deceased) 96.2% 98.4% 0.160
Recipient age (years) 47.8 ± 13.9 52.6 ± 12.9 0.001
Recipient age (>60) 23.1% 32.2% 0.066
Current PRA 18.5 ± 27.9 3.2 ± 12.9 <0.001
Peak PRA 29.7 ± 37.0 8.1 ± 21.3 <0.001
PRA > 15% 35.4% 5.3% <0.001
RRT length 4.8 ± 5.2 3.1 ± 3.5 <0.001
Recipient diabetes 12.5% 10.2% 0.169
Transplant number (>1) 26.9% 13.3% 0.001
Recipient HCV 9.8% 6.7% 0.298
Body mass index 24.7 ± 5.0 25.4 ± 4.2 0.221
Mismatches 3.4 ± 1.3 3.6 ± 1.1 0.338
Cold ischaemia time (h) 16.3 ± 6.3 18.4 ± 5.4 0.002
RRT, renal replacement therapy; CVA, cerebro-vascular accident.
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therapy was not the same for all groups of patients. Pa-
tients younger than 55 years who received induction ther-
apy had a significantly higher allograft survival than the
others who did not receive induction treatment (P =
0.008). Also, 15.1% of the patients who received induction
therapy had graft loss vs 17.6% without induction. There
were, however, no graft survival advantages in those pa-
tients older than 55 years who received induction therapy
(graft loss after induction therapy 10.5% vs 10.3% without
induction, P = 0.758).
Patients with current PRA lower than 20% benefited
more by receiving induction therapy (graft loss after induc-
tion therapy 13.2% vs 16.0% without induction, P =
0.014). On the other hand, patients with current PRA equal
to or higher than 20% showed no advantage for being trea-
ted with induction (graft loss after induction therapy
20.5% vs 27.1% without induction, P = 0.224).
Discussion
Unlike US data, we cannot find a trend toward increasing
use of induction drugs in kidney transplantation between
1990 and 2002 in Spain. Moreover, such use is quite lower
than the reported induction use in the USA (from 46% in
1995 to 72% in 2004) [9]. It seems that induction therapy
has been used at a higher rate in Spain beyond 2002, but
we cannot conclude this from our data. Clearly, the use of
the monoclonal antibody OKT3 has waned in Spain pro-
gressively (1.0% in 2002), similar to that reported by US
and ANZDATA registries [9,10]. Nowadays, depleting in-
duction therapy is based on polyclonal antibodies in Spain,
the USA, Australia and New Zealand [9,10]. From the
Brennan et al. report comparing Thymoglobulin with AT-
GAM in 1999, Thymoglobulin has become the preferred
polyclonal agent [9,19], although this finding could not
be demonstrated in our study since that polyclonal induc-
tion use registry includes different agents.
All over theworld, non-depleting anti-CD25 monoclonal
antibodies are being used in a higher percentage of patients.
Anti-CD25 antibodies were used in 27.2% of patients in
2002 in Spain, in 57.1% in 2005 in Australia and
New Zealand and in 21% in 2004 in the USA [9,10].
This increasing use can be attributed both to initial
studies [20–22] and to further meta-analysis that have
shown that anti-CD25 antibodies reduce acute rejection
rates compared with placebo [4–6]. Together with their ef-
ficiency reducing rejection rates, the costs with anti-CD25
are lower compared to transplant without induction [23].
As a result of these data, a progressively increasing use
of anti-CD25 antibodies is expected in future years.
The use of induction antibodies varies between centres,
although there are few reported data about this issue [1].
The wide range of induction use (1.6–98.1%), polyclonal
antibody use (0–78%) and anti-CD25 use (0–73%) in
Spain can only be partly explained by differences in pop-
ulation characteristics in Spanish centres. Some such cen-
tres in Spain have a very high rate of diabetic recipients
or re-transplants. However, lack of consensus about spe-
cific indications seems the main cause of this heteroge-
neity. The global Spanish trend to use induction drugs in
a higher rate of patients at each centre, at more similar
rates among the different centres and mainly anti-CD25
antibodies, would indicate that induction indications will
be more homogeneous in the future.
No previous report has analysed which kidney recipients
have received induction therapy in such a high number of
patients. Prospective induction trials have defined ‘high-
risk patients’ in several ways. For example, Noël et al.
defined this kind of patient as having one or more of
the following risk factors: a current PRA ≥ 30%, a peak
PRA ≥ 50%, scheduled for a second transplantation
when the first graft was lost to rejection within 2 years
or receiving a third or fourth kidney graft [24]. By con-
trast, Brennan et al. designed their trial to include pa-
tients at risk for both acute rejection and delayed graft
function, taking into account cold ischaemia time, donor
age, non-heart-beating donor, high-dose inotropic support
of donor, repeated transplantation, current PRA > 20%,
black race and mismatches [25]. In our retrospective
study, induction therapy was used in older recipients, with
a higher PRA rate, receiving a second or more transplan-
tation, with more mismatches and diabetic. Among stud-
ied variables, no donor characteristic was related with
induction indication. Some of these recipient variables
were related with a higher immunological risk for acute
rejection, such as PRA, re-transplantation and mismatches,
while the recipient age and diabetes are more related with
the risk for delayed graft function and the intention to use
steroid or calcineurin-inhibitor minimization strategies.
Surprisingly, the use of induction therapy in the USA
was no different among groups with varying PRA [9].
By contrast, most of the US patients on steroid-avoidance
regimens received induction drugs [9].
As several meta-analyses have shown that induction
therapy improves kidney transplant outcomes in a cost-
effectiveway compared with no induction, a possible future
Fig. 2. Kaplan–Meier analysis for graft survival. Upper line represents
those patients receiving induction therapy. Lower line represents
patients not receiving such therapy.
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transplants [3–6,23]. In this case, the doubt will be what
induction we must use (polyclonal antibodies, mainly
Thymoglobulin, or anti-CD25 antibodies). Nowadays,
the optimal prophylactic induction immunosuppressive
therapy remains controversial. Several trials including
low-immunological-risk patients have found similar rates
of acute graft rejection and graft and patient survival, with
higher rates of cytomegalovirus infection with polyclonal
antibodies compared with anti-CD25 antibodies [26]. In
high-risk patients, the rate of acute rejection was greater
in those patients treated with anti-CD25 antibodies, but
graft and patient survival was the same at the first and
fifth years [24,25,27]. Our study cannot allow us to com-
pare outcomes of patients receiving polyclonal antibodies
vs anti-CD25 antibodies, but we analysed which kidney
graft recipients were prescribed either of them. Thus, Span-
ish centres used polyclonal antibodies instead of anti-CD25
in patients with a higher acute rejection risk (high PRA and
re-transplants) but with a lower infection risk due to their
younger age.
It has been difficult to know the effect of induction ther-
apy on long-term graft survival [1]. In a single-centre
study, 1-year graft survival was better in patients receiving
polyclonal induction (93% vs 79%), but no difference was
observed from the second to the 20th year in graft survival
[16]. A meta-analysis of seven randomized trials compar-
ing lymphocyte-depleting induction with no-induction
therapy showed a statistically significant improvement in
2-year graft survival in patients treated with induction
drugs [28]. This improvement did not remain significant
in 5-year graft survival [3]. Another meta-analysis includ-
ing 17 trials and 2786 patients found no differences in
graft loss at the first and third years between those patients
treated and those not treated with anti-CD25 antibodies
[4]. In a recent retrospective USRDS analysis between
1997 and 2004, Gill et al. reported no differences in 1-
and 5-year graft survival in low-risk renal transplant reci-
pients receiving polyclonal antibodies vs no-induction
therapy [29]. The benefits of using induction therapy must
be weighed against the potential risk of overimmunosup-
pression, including the risks of infection and malignancy
that may occur years after the induction use. Lymphocyte-
depleting induction is related with a significantly increased
risk for early deaths within 6 months and after 6 months
post-transplantation in relation with infection, malignancy
and cardiovascular problems [17].
However, patients with a kidney surviving more than
1 year who received induction therapy in Spain showed
a significantly better long-term graft survival with the
same patient survival than those not treated with induction
drugs. Induction therapy exerts its protective role over
graft survival independently of other confounding factors,
such as acute rejection. This result cannot be compared
with previous studies due to the fact that we analysed only
kidneys functioning beyond the first year. The high num-
ber of patients in our study allows us to assert that an im-
munosuppressive regimen including induction drugs can
improve long-term graft survival, this favourable effect
being different according to which groups received treat-
ment. In our study, recipients younger than 55 years and
with low PRA benefited more from receiving induction
therapy.
In conclusion, from 1990 to 2002, the use of induction
therapy in Spain changed, with a progressive reduction in
the use of OKT3 and an increasing use of anti-CD25 anti-
bodies. There were great differences in the rate of induction
use among the different centres, although with a common
t r e n dt oi t su s ei nm o r ep a t i e n t s .I n d u c t i o nt h e r a p yw a s
mainly prescribed in patients with a higher rejection risk
(higher PRA titres and mismatches and re-transplants)
and/or needing calcineurin-inhibitor or steroid minimiza-
tion regimens to prevent delayed graft function and other
secondary effects (older and diabetic recipients). Lastly,
induction therapy has a protective role in long-term graft
survival.
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